Last reviewed September 15, 2026. Educational content for adults 21+. This article is not medical advice and does not recommend a dose or use. Kiody does not sell concentrated 7-hydroxymitragynine (7-OH) products.
The short answer: corynantheidine is a naturally occurring minor indole alkaloid found in Mitragyna speciosa leaf. It is not mitragynine, 7-OH, morphine, oxycodone or fentanyl. Laboratory studies suggest that purified corynantheidine can interact with opioid and adrenergic receptors, but its classification depends on the assay: older work described functional mu-opioid antagonism, while a 2021 study found partial mu-opioid agonism in a mouse-receptor system. No controlled human study has isolated corynantheidine’s effects.
That evidence does not make ordinary botanical kratom leaf equivalent to a standardized pharmaceutical opioid. Leaf is a variable multi-constituent plant material; morphine, oxycodone and pharmaceutical fentanyl are defined drugs with established clinical pharmacology, labeled strengths and documented dose-related respiratory risk. A fair comparison must keep those categories visible.
Corynantheidine is one constituent of botanical kratom leaf
Kratom is the leaf of Mitragyna speciosa (Korth.) Havil., the accepted botanical name recorded by Kew’s Plants of the World Online. Researchers have identified dozens of indole and oxindole alkaloids in the species. Mitragynine is usually the most abundant quantified alkaloid in leaf, while corynantheidine is among the less abundant constituents.
“Minor” describes relative abundance, not insignificance or safety. A low-concentration molecule may still be useful for identifying a botanical fingerprint, studying structure–activity relationships or understanding mixture-level interactions. But an experiment with purified corynantheidine cannot be transferred directly to leaf, because leaf contains other constituents and exposes them together.
| Material or system | What it can show | What it cannot establish alone |
|---|---|---|
| Authenticated kratom leaf | Whether corynantheidine occurs in a defined sample and its measured concentration | A universal percentage for every tree, season or lot |
| Commercial whole-leaf powder | The chemical profile of the submitted lot | Composition of every product sold as kratom |
| Broad-spectrum extract | Composition after a specific extraction process | Equivalence to the same mass of ordinary leaf |
| Purified corynantheidine | Compound-specific binding, signaling, enzyme or animal findings | The combined behavior of whole leaf in people |
| Human plasma or urine | Exposure or metabolites under the study’s conditions | Which constituent caused an effect |
| Prescription opioid | Clinical pharmacology of a defined drug and dosage form | The pharmacology of corynantheidine or botanical leaf |
Chemistry and identity
Corynantheidine belongs to the corynanthe-type monoterpene indole alkaloids. NIH’s PubChem record lists the molecular formula C22H28N2O3. Structural details—including stereochemistry and the pattern of oxygen-containing groups—change how the molecule fits receptor sites and how enzymes transform it. View the NIH PubChem record.
Corynantheidine should not be confused with corynoxine, corynoxine B or corynantheidine pseudoindoxyl derivatives. Oxidation or rearrangement changes the scaffold and can change receptor efficacy substantially. A paper about a corynantheidine-derived pseudoindoxyl is not evidence about the natural parent alkaloid in leaf.
How much corynantheidine is in natural leaf?
No single percentage describes every leaf. Genetics, geography, season, leaf age, post-harvest handling, storage and analytical method can change a reported result. The denominator also matters: percent of dry leaf, percent of total alkaloids, milligrams per gram and percent of an enriched fraction are different measurements.
Sharma and colleagues validated a UPLC–MS/MS method for ten kratom alkaloids and applied it to authenticated leaf extracts, lyophilized teas, commercial products and alkaloid-rich fractions. Corynantheidine was measurable across some matrices, but the mixed sample set was not a random survey of the global leaf supply. Concentrated fractions must not be presented as normal leaf. Read Sharma et al., 2019.
Manwill and colleagues later used quantitative analysis to distinguish chemotypes among authenticated plants and products. The study supports composition variability, not a universal “strain” formula or fixed corynantheidine value. Read Manwill et al., 2022.
Why analytical separation matters
Targeted liquid chromatography coupled with tandem mass spectrometry is commonly used to measure kratom alkaloids. Chromatography separates compounds in time; mass spectrometry then detects selected ions and fragments. Closely related alkaloids can share nominal mass or fragment patterns, so authentic reference standards, retention-time resolution and method validation matter.
Flores-Bocanegra and colleagues combined nuclear magnetic resonance, high-resolution mass spectrometry and chromatographic methods to update structural assignments for numerous kratom alkaloids. Their work shows why reference-quality structural characterization comes before routine quantification. Read Flores-Bocanegra et al., 2020.
A 2026 University of Florida-led method expanded measurement in human plasma to 12 parent alkaloids and five metabolites, including corynantheidine and 9-hydroxycorynantheidine. It was applied to clinical samples from four regular kratom users. That small application demonstrates analytical feasibility; it does not define population pharmacokinetics or isolate corynantheidine’s effects. Read Kanumuri et al., 2026.
Early opioid-receptor evidence called it an antagonist
Older functional-tissue experiments described corynantheidine as an opioid antagonist because it reduced an opioid-driven response in guinea-pig ileum. That model was useful for identifying receptor-related activity, but it did not use purified human receptors, did not administer ordinary leaf and did not measure a clinical outcome.
“Antagonist” means a compound reduces another ligand’s receptor response under defined conditions. It does not automatically mean that the molecule protects a person from opioid overdose, reverses respiratory depression or cancels stronger agonists. Those would require direct, dose-controlled evidence that does not exist for corynantheidine.
The 2020 receptor study added adrenergic evidence
Obeng and colleagues compared selected purified kratom alkaloids in receptor-binding, metabolic-stability and protein-binding experiments. Corynantheidine showed affinity for the human mu-opioid receptor and markedly stronger affinity at the alpha-1D adrenergic receptor than mitragynine in that panel. Its three-dimensional conformation was compared with yohimbine, an adrenergic antagonist. Read Obeng et al., 2020.
Binding does not tell us whether a ligand activates or blocks a receptor, how much reaches that receptor after oral leaf use, or what a person experiences. Alpha-1 receptors participate in vascular and nervous-system signaling, but an in-vitro affinity value is not evidence that leaf produces a specific cardiovascular or psychological outcome through corynantheidine.
The research was supported by NIH institutes and reported no conflicts of interest. It remains preclinical and compound-specific.
A 2021 study classified purified corynantheidine as a partial mu agonist
Chakraborty and colleagues examined purified minor kratom alkaloids across opioid-receptor binding and functional assays. In their mouse mu-opioid-receptor system, corynantheidine behaved as a selective partial agonist, reaching about 37% of the reference agonist’s maximum response. Its oxindole relative corynoxine behaved differently, reinforcing that related names do not mean identical pharmacology. Read Chakraborty et al., 2021.
A partial agonist activates a receptor but produces a lower maximum response than the reference full agonist in that particular assay. This classification depends on receptor species, receptor density, cell background, signaling readout and reference ligand. It is not a direct measure of breathing, impairment, dependence or real-world potency.
The difference between older antagonist findings and later partial-agonist findings is not resolved by choosing the preferred label. The studies used different systems. Standardized work at human receptors and direct human pharmacology are still needed.
Rat pharmacokinetics are not human instructions
King and colleagues developed a validated UPLC–MS/MS method for corynantheidine in rat plasma, then studied purified corynantheidine after intravenous and oral administration in male Sprague–Dawley rats; the oral pharmacokinetic group included four animals. The study reported measurable oral bioavailability, prolonged absorption and broad tissue distribution; imaging mass spectrometry detected the compound in selected brain regions. Read King et al., 2020.
This was a preclinical method-development and pharmacokinetic study—not a safety trial, a whole-leaf study or a human experiment. Intravenous administration bypasses the gut and first-pass metabolism. Oral rat exposure still cannot be converted into a human dose or a quantity of leaf because species, route, bioavailability, metabolism, plant composition and product format differ.
Enzyme studies raise questions, not proven clinical interactions
Kamble and colleagues tested major kratom alkaloids against cytochrome P450 enzymes in vitro. Corynantheidine inhibited CYP2D6 under the laboratory conditions. These experiments identify mechanisms worth studying; they do not establish that ordinary leaf changes a particular medicine’s exposure in people. Read Kamble et al., 2020.
A 2023 study tested purified alkaloids and multiple kratom extracts against carboxylesterase 1 (CES1), an enzyme that processes several medicines. Corynantheidine produced reversible mixed-type inhibition in vitro. In a separate experiment, a five-alkaloid mixture that excluded corynantheidine because no human peak-concentration value was available produced only small CES1 inhibition at concentrations approximating measured human exposure. The authors concluded that a clinically important CES1 interaction appeared unlikely across the studied assumptions while emphasizing the lack of high-exposure and chronic-use pharmacokinetic data. Read Melchert et al., 2023.
People who use medicines should tell a qualified clinician or pharmacist about kratom, especially when a drug has a narrow therapeutic range. Kiody’s kratom interactions guide separates controlled human data from laboratory predictions.
Corynantheidine versus pharmaceutical opioids: a category-level comparison
The scientifically valid comparison is not “natural equals safe” versus “pharmaceutical equals deadly.” It is a comparison of evidence categories. A minor constituent embedded in variable leaf, a purified research chemical and a regulated medicine are different objects.
| Category | What is administered | Receptor evidence | Human evidence | Respiratory-risk evidence |
|---|---|---|---|---|
| Ordinary botanical kratom leaf | A variable mixture of many constituents, usually with mitragynine predominant and corynantheidine minor | Cannot be reduced to one alkaloid’s assay result | Small controlled studies and larger observational research exist, but product and pattern vary | No corynantheidine-specific human respiratory study; uncertainty and interactions remain |
| Purified corynantheidine | One isolated compound used in laboratory or animal research | Older functional antagonism; later partial mu agonism in a mouse-receptor assay; adrenergic binding | No controlled human isolate trial identified | No controlled human respiratory study identified |
| Morphine | A defined pharmaceutical active ingredient in labeled dosage forms | Established mu-opioid agonist pharmacology | Extensive clinical pharmacology and prescribing data | Official labeling warns of serious, life-threatening or fatal respiratory depression |
| Oxycodone | A defined semisynthetic opioid medicine in labeled strengths | Established opioid-agonist pharmacology | Extensive clinical and postmarket evidence | Official labeling identifies serious, life-threatening or fatal respiratory depression |
| Pharmaceutical fentanyl | A highly potent defined opioid in tightly specified medical dosage forms | Established mu-opioid agonist pharmacology | Extensive clinical pharmacology; formulation and route are critical | Official labeling warns of fatal respiratory depression and restricts some forms to opioid-tolerant patients |
Why morphine is a useful laboratory reference—but not proof of equivalence
Morphine is commonly used as a reference because its mu-opioid pharmacology is well characterized. FDA-maintained DailyMed labeling describes morphine as a pure opioid agonist and lists respiratory depression among its pharmacological effects. The label warns that serious, life-threatening or fatal respiratory depression may occur, particularly during treatment initiation or after a dose increase. Read the current DailyMed morphine label reviewed September 15, 2026.
Researchers may normalize a cell response to a reference agonist or compare binding values across compounds. That does not make corynantheidine “a weaker morphine” or permit a numerical conversion between the two. A 37% maximum response in one engineered cell assay does not predict 37% of morphine’s analgesia, euphoria, respiratory depression or dependence liability in a person.
Oxycodone is also not a botanical proxy
Oxycodone is a defined prescription opioid agonist. Its official label specifies active ingredient, tablet strengths, indications, contraindications, clinical pharmacology and adverse reactions. The label warns that serious, life-threatening or fatal respiratory depression can occur, especially during initiation or following an increase. Read the current DailyMed oxycodone label reviewed September 15, 2026.
Corynantheidine has no comparable approved indication, validated human dose, prescribing label or controlled human efficacy program. The lack of such evidence does not prove equal danger, greater safety or no biological activity. It means the certainty levels are different.
Pharmaceutical fentanyl must be separated from illicitly manufactured fentanyl
Fentanyl is a potent mu-opioid agonist used medically in specific formulations and settings. Official labeling for fentanyl transdermal systems warns of respiratory depression and limits use to opioid-tolerant patients. Read the current DailyMed fentanyl patch label reviewed September 15, 2026.
Pharmaceutical fentanyl and illicitly manufactured fentanyl share the active compound but differ in production controls, labeling, intended use, distribution and exposure context. Mortality statistics often use categories that overlap and may combine multiple drugs; they cannot be added casually or used to assign a pharmaceutical-versus-illicit source without the underlying data. This compound guide therefore does not turn mortality totals into a marketing comparison.
What laboratory “bias” does not prove
Some kratom alkaloids show lower beta-arrestin recruitment than classical opioids in particular receptor systems. That observation has encouraged research into whether signaling profiles could separate desired and adverse effects. Modern pharmacology, however, does not support treating low beta-arrestin recruitment as a universal safety switch. G-protein signaling can contribute to respiratory depression, receptor reserve changes apparent bias, and metabolites may have different efficacy.
No published controlled human respiratory study of purified corynantheidine was identified for this review. Results for isolated mitragynine, 7-OH, mitragynine pseudoindoxyl or other derivatives cannot be reassigned to corynantheidine. A finding for one isolated compound also cannot certify the respiratory safety of every leaf lot or use pattern.
Corynantheidine is not 7-OH, MGPI, MGM-15 or MGM-16
Corynantheidine is a natural minor leaf alkaloid. 7-hydroxymitragynine is a different oxidized mitragynine-related compound that may occur at trace levels or form after harvest and through metabolism; concentrated or manufactured 7-OH products substantially change that relationship. Mitragynine pseudoindoxyl (MGPI), MGM-15 and MGM-16 are also separate molecules.
Receptor potency, respiratory findings, dependence liability or regulatory treatment cannot be transferred among these compounds. Kiody’s botanical kratom leaf versus concentrated 7-OH guide explains this distinction.
What this evidence does not establish about overdose or mortality
No validated human lethal dose has been established for purified corynantheidine or for the corynantheidine naturally embedded in ordinary leaf. It would be scientifically invalid and potentially harmful to convert injected animal doses into kilograms of human leaf. Species, route, absorption, metabolism, product composition, co-exposures and individual vulnerability prevent that calculation.
Forensic and surveillance records often detect mitragynine or use a broad “kratom” category without retaining and chemically authenticating the consumed product. Those records usually cannot tell whether the material was unaltered leaf, an extract, an enhanced product, a concentrated/manufactured 7-OH product or an adulterated mixture. Mitragynine detection does not identify the formulation or prove sole causation. Incomplete evidence also cannot prove that unaltered leaf carries zero risk.
Claim check: evidence versus overstatement
| Claim | Best available evidence | What remains unproven |
|---|---|---|
| “Corynantheidine is the opioid in kratom.” | It is one minor alkaloid among many; mitragynine is commonly the predominant measured leaf alkaloid. | That one constituent explains whole-leaf pharmacology. |
| “It is definitely an opioid antagonist.” | Older tissue work reported antagonism; a later receptor study reported partial agonism. | One assay-independent classification or a human clinical effect. |
| “Partial agonist means partially safe.” | Partial agonism describes maximum response in a particular assay. | Human respiratory safety, impairment, dependence or interaction risk. |
| “Rat oral bioavailability tells us how much leaf a person can take.” | Rat PK describes purified corynantheidine under defined routes. | A human dose, duration, lethal amount or whole-leaf conversion. |
| “Kratom leaf is chemically the same as morphine.” | Leaf is a variable botanical mixture; morphine is a defined pharmaceutical agonist. | Product, exposure or clinical equivalence. |
| “Fentanyl data prove what corynantheidine does.” | Fentanyl is a clinically characterized potent mu agonist with explicit respiratory warnings. | Corynantheidine’s human potency or respiratory effect. |
| “No human isolate trial proves it is harmless.” | No controlled human isolate study was identified. | Safety; absence of evidence is not proof of zero risk. |
| “A kratom-associated case proves natural corynantheidine caused it.” | Most case records do not authenticate the consumed product or provide a full alkaloid profile. | Leaf identity and corynantheidine-specific causation. |
Research priorities
- Independent mapping of corynantheidine across authenticated genetics, regions, seasons, leaf ages and post-harvest conditions.
- Interlaboratory validation with authenticated reference standards and chromatography that resolves related alkaloids.
- Standardized functional studies at human mu, delta, kappa and adrenergic receptors using multiple signaling endpoints.
- Metabolite identification in human systems, including the stability and activity of 9-hydroxycorynantheidine.
- Human pharmacokinetic studies using fully characterized ordinary-leaf preparations and reporting all major alkaloids.
- Direct respiratory and cardiovascular pharmacology without inferring outcomes from receptor binding alone.
- Mixture studies that test whether low-abundance alkaloids modify mitragynine or 7-OH signaling.
- Transparent replication with funding, conflicts, product chemistry and full methods reported.
Frequently asked questions
Is corynantheidine naturally present in kratom leaf?
Yes. It has been isolated and quantified in Mitragyna speciosa materials. It is generally described as a minor alkaloid, and its concentration varies across samples and methods.
Is corynantheidine the same as mitragynine?
No. They are different indole alkaloids with different structures, analytical behavior and reported receptor profiles.
Is corynantheidine an opioid agonist or antagonist?
Published classifications differ by experimental system. Older functional-tissue work described antagonism, while a 2021 mouse-receptor study found selective partial mu agonism. Neither finding alone establishes what the compound does in people.
Has purified corynantheidine been tested in humans?
No controlled human trial administering isolated corynantheidine was identified. A 2026 analytical method measured corynantheidine and metabolites in human plasma after kratom use, but it did not isolate the compound’s effects.
Does corynantheidine make natural kratom leaf equivalent to morphine?
No. Leaf is a variable mixture containing many constituents. Morphine is a defined pharmaceutical opioid with extensive clinical pharmacology and explicit labeling for respiratory, dependence and interaction risks.
Is it safer than oxycodone or fentanyl?
There is not enough controlled human evidence to rank purified corynantheidine against those drugs for safety. Pharmaceutical opioids have well-established respiratory risks; corynantheidine lacks comparable human testing. Different evidence depth is not a numerical safety comparison.
Can corynantheidine interact with medicines?
Laboratory studies raise CYP2D6 and CES1 questions, but they do not establish a clinical interaction from ordinary leaf. A clinician or pharmacist can evaluate a person’s actual medicines and health factors.
Is corynantheidine concentrated 7-OH?
No. They are distinct molecules. Natural leaf, extracts, enhanced products, concentrated/manufactured 7-OH and other derivatives should not be treated as interchangeable.
Primary evidence trail
- Sharma A, et al. Simultaneous Quantification of Ten Key Kratom Alkaloids. Drug Testing and Analysis. 2019. Validated UPLC–MS/MS across several plant and product matrices; mixed matrices do not define a universal leaf range.
- Obeng S, et al. Investigation of the Adrenergic and Opioid Binding Affinities of Selected Kratom Alkaloids. Journal of Medicinal Chemistry. 2020. Purified-compound receptor, stability and binding experiments; NIH-funded, no conflicts declared.
- King TI, et al. Bioanalytical Method Development and Validation of Corynantheidine. Journal of Pharmaceutical and Biomedical Analysis. 2020. Purified-compound rat pharmacokinetics and imaging; not a human or whole-leaf study.
- Flores-Bocanegra L, et al. The Chemistry of Kratom: Updated Characterization Data and Methods. Journal of Natural Products. 2020. Structural chemistry using NMR and high-resolution mass spectrometry.
- Kamble SH, et al. Exploration of Cytochrome P450 Inhibition Mediated Drug–Drug Interaction Potential of Kratom Alkaloids. Toxicology Letters. 2020. In-vitro CYP experiments; not proof of a clinical interaction.
- Chakraborty S, et al. Kratom Alkaloids as Probes for Opioid Receptor Function. ACS Chemical Neuroscience. 2021. Purified minor alkaloids in receptor and preclinical systems; corynantheidine was a partial mu agonist in the reported mouse-receptor assay.
- Manwill PK, et al. Kratom Validation: Quantitative Analysis Reveals Chemotypes. Planta Medica. 2022. Authenticated plants and products; not a universal botanical specification.
- Melchert PW, et al. An In Vitro Evaluation of Kratom on Carboxylesterase 1. Chemico-Biological Interactions. 2023. Extract and purified-alkaloid CES1 experiments plus a physiologically based screen; clinical interaction uncertainty remains.
- Kanumuri SRR, et al. Simultaneous Quantification of Seventeen Kratom Alkaloids and Metabolites in Human Plasma. Pharmaceutical Biology. 2026. Validated plasma method applied to samples from four regular users; analytical, not effects, evidence.
- DailyMed. Morphine Sulfate Extended-Release Tablets. Official current pharmaceutical labeling reviewed September 15, 2026.
- DailyMed. Oxycodone Hydrochloride Tablets. Official current pharmaceutical labeling reviewed September 15, 2026.
- DailyMed. Fentanyl Transdermal System. Official current pharmaceutical labeling reviewed September 15, 2026.
Editorial boundary: this guide explains evidence; it does not claim that kratom, corynantheidine or a prescription opioid treats, cures or prevents a condition outside approved medical labeling. It provides no dosing, lethal-dose or overdose instructions. If you take medication, have a health condition, are pregnant or breastfeeding, or experience concerning symptoms, consult a qualified health professional. Do not drive or operate heavy machinery while impaired.